ZA200601852B - Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents - Google Patents

Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents Download PDF

Info

Publication number: ZA200601852B
Authority: ZA; South Africa
Prior art keywords: defibrotide; mammalian; affected; active ingredient; tumour
Prior art date: 2003-09-05

Application number

ZA200601852A

Other languages

English (en)

Inventor

Ferro Laura Iris

Iacobelli Massimo

Richardson Paul

Original Assignee

Gentium Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-09-05

Filing date

2004-08-27

Publication date

2007-06-27

2004-08-27 Application filed by Gentium Spa filed Critical Gentium Spa

2007-06-27 Publication of ZA200601852B publication Critical patent/ZA200601852B/en

Links

JNWFIPVDEINBAI-UHFFFAOYSA-N [5-hydroxy-4-[4-(1-methylindol-5-yl)-5-oxo-1H-1,2,4-triazol-3-yl]-2-propan-2-ylphenyl] dihydrogen phosphate Chemical compound C1=C(OP(O)(O)=O)C(C(C)C)=CC(C=2N(C(=O)NN=2)C=2C=C3C=CN(C)C3=CC=2)=C1O JNWFIPVDEINBAI-UHFFFAOYSA-N 0.000 title claims abstract description 64
229960004120 defibrotide Drugs 0.000 title claims abstract description 63
230000000259 anti-tumor effect Effects 0.000 title claims abstract description 12
238000009472 formulation Methods 0.000 title claims abstract description 10
239000000203 mixture Substances 0.000 title claims abstract description 10
239000002246 antineoplastic agent Substances 0.000 title 1
230000009471 action Effects 0.000 claims abstract description 12
239000004480 active ingredient Substances 0.000 claims abstract description 9
239000013543 active substance Substances 0.000 claims abstract 2
206010028980 Neoplasm Diseases 0.000 claims description 16
238000000034 method Methods 0.000 claims description 12
DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims description 11
206010035226 Plasma cell myeloma Diseases 0.000 claims description 11
229960001924 melphalan Drugs 0.000 claims description 10
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 10
QPNKYNYIKKVVQB-UHFFFAOYSA-N crotaleschenine Natural products O1C(=O)C(C)C(C)C(C)(O)C(=O)OCC2=CCN3C2C1CC3 QPNKYNYIKKVVQB-UHFFFAOYSA-N 0.000 claims description 7
QVCMHGGNRFRMAD-XFGHUUIASA-N monocrotaline Chemical compound C1OC(=O)[C@](C)(O)[C@@](O)(C)[C@@H](C)C(=O)O[C@@H]2CCN3[C@@H]2C1=CC3 QVCMHGGNRFRMAD-XFGHUUIASA-N 0.000 claims description 7
QVCMHGGNRFRMAD-UHFFFAOYSA-N monocrotaline Natural products C1OC(=O)C(C)(O)C(O)(C)C(C)C(=O)OC2CCN3C2C1=CC3 QVCMHGGNRFRMAD-UHFFFAOYSA-N 0.000 claims description 7
201000008275 breast carcinoma Diseases 0.000 claims description 6
CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 claims description 5
229930012538 Paclitaxel Natural products 0.000 claims description 5
229960004397 cyclophosphamide Drugs 0.000 claims description 5
229960001592 paclitaxel Drugs 0.000 claims description 5
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims description 5
208000034578 Multiple myelomas Diseases 0.000 claims description 3
239000007864 aqueous solution Substances 0.000 claims description 2
-1 monocrotalirze Chemical compound 0.000 claims description 2
239000000546 pharmaceutical excipient Substances 0.000 claims description 2
239000002671 adjuvant Substances 0.000 claims 1
239000004615 ingredient Substances 0.000 claims 1
238000004519 manufacturing process Methods 0.000 claims 1
MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 claims 1
238000002512 chemotherapy Methods 0.000 description 11
210000004027 cell Anatomy 0.000 description 9
230000000694 effects Effects 0.000 description 9
230000003013 cytotoxicity Effects 0.000 description 8
231100000135 cytotoxicity Toxicity 0.000 description 8
201000000050 myeloid neoplasm Diseases 0.000 description 8
241000699670 Mus sp. Species 0.000 description 7
239000003795 chemical substances by application Substances 0.000 description 6
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 5
229960001196 thiotepa Drugs 0.000 description 5
230000004614 tumor growth Effects 0.000 description 5
229940100198 alkylating agent Drugs 0.000 description 4
239000002168 alkylating agent Substances 0.000 description 4
230000001988 toxicity Effects 0.000 description 4
231100000419 toxicity Toxicity 0.000 description 4
208000012766 Growth delay Diseases 0.000 description 3
241001465754 Metazoa Species 0.000 description 3
241000699666 Mus <mouse, genus> Species 0.000 description 3
241000700159 Rattus Species 0.000 description 3
230000002634 anti-blastic effect Effects 0.000 description 3
239000008280 blood Substances 0.000 description 3
210000004369 blood Anatomy 0.000 description 3
231100000433 cytotoxic Toxicity 0.000 description 3
230000001472 cytotoxic effect Effects 0.000 description 3
210000002889 endothelial cell Anatomy 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000001681 protective effect Effects 0.000 description 3
230000004083 survival effect Effects 0.000 description 3
241000283690 Bos taurus Species 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
230000006907 apoptotic process Effects 0.000 description 2
VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 description 2
230000037396 body weight Effects 0.000 description 2
229960004562 carboplatin Drugs 0.000 description 2
238000004113 cell culture Methods 0.000 description 2
238000011393 cytotoxic chemotherapy Methods 0.000 description 2
230000003511 endothelial effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
230000007246 mechanism Effects 0.000 description 2
230000004044 response Effects 0.000 description 2
210000004881 tumor cell Anatomy 0.000 description 2
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
206010058467 Lung neoplasm malignant Diseases 0.000 description 1
206010027458 Metastases to lung Diseases 0.000 description 1
108091034117 Oligonucleotide Proteins 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000000181 anti-adherent effect Effects 0.000 description 1
230000000719 anti-leukaemic effect Effects 0.000 description 1
230000002785 anti-thrombosis Effects 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
229960005243 carmustine Drugs 0.000 description 1
230000021164 cell adhesion Effects 0.000 description 1
230000008614 cellular interaction Effects 0.000 description 1
238000009104 chemotherapy regimen Methods 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
230000002596 correlated effect Effects 0.000 description 1
229940127089 cytotoxic agent Drugs 0.000 description 1
239000002254 cytotoxic agent Substances 0.000 description 1
231100000599 cytotoxic agent Toxicity 0.000 description 1
230000003111 delayed effect Effects 0.000 description 1
MCWXGJITAZMZEV-UHFFFAOYSA-N dimethoate Chemical compound CNC(=O)CSP(=S)(OC)OC MCWXGJITAZMZEV-UHFFFAOYSA-N 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
239000002158 endotoxin Substances 0.000 description 1
210000002919 epithelial cell Anatomy 0.000 description 1
230000003480 fibrinolytic effect Effects 0.000 description 1
229960000390 fludarabine Drugs 0.000 description 1
230000012010 growth Effects 0.000 description 1
230000002008 hemorrhagic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
230000005917 in vivo anti-tumor Effects 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
208000028867 ischemia Diseases 0.000 description 1
208000032839 leukemia Diseases 0.000 description 1
229920006008 lipopolysaccharide Polymers 0.000 description 1
238000010172 mouse model Methods 0.000 description 1
230000009826 neoplastic cell growth Effects 0.000 description 1
239000002773 nucleotide Substances 0.000 description 1
210000000056 organ Anatomy 0.000 description 1
230000002093 peripheral effect Effects 0.000 description 1
108091033319 polynucleotide Proteins 0.000 description 1
239000002157 polynucleotide Substances 0.000 description 1
102000040430 polynucleotide Human genes 0.000 description 1
231100000683 possible toxicity Toxicity 0.000 description 1
238000010149 post-hoc-test Methods 0.000 description 1
239000003805 procoagulant Substances 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000009467 reduction Effects 0.000 description 1
159000000000 sodium salts Chemical class 0.000 description 1
210000000130 stem cell Anatomy 0.000 description 1
239000000126 substance Substances 0.000 description 1
208000011580 syndromic disease Diseases 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
235000013311 vegetables Nutrition 0.000 description 1
230000003442 weekly effect Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/665—Phosphorus compounds having oxygen as a ring hetero atom, e.g. fosfomycin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Biochemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

ZA200601852A 2003-09-05 2004-08-27 Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents ZA200601852B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
IT001714A ITMI20031714A1 (it)	2003-09-05	2003-09-05	Formazioni ad azione antitumorale.

Publications (1)

Publication Number	Publication Date
ZA200601852B true ZA200601852B (en)	2007-06-27

Family

ID=37064585

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200601852A ZA200601852B (en)	2003-09-05	2004-08-27	Anti-tumor formulations comprising defibrotide alone or in combination with other anti-tumor agents

Country Status (23)

Country	Link
US (2)	US8551967B2 (de)
EP (1)	EP1660100B1 (de)
JP (1)	JP4671962B2 (de)
KR (1)	KR20060061367A (de)
CN (1)	CN100490820C (de)
AT (1)	ATE399558T1 (de)
AU (1)	AU2004269896B2 (de)
BR (1)	BRPI0414114A (de)
CA (1)	CA2537226C (de)
DE (1)	DE602004014787D1 (de)
DK (1)	DK1660100T3 (de)
ES (1)	ES2308223T3 (de)
IL (1)	IL173785A0 (de)
IS (1)	IS8334A (de)
IT (1)	ITMI20031714A1 (de)
MX (1)	MXPA06002489A (de)
NO (1)	NO20061402L (de)
PT (1)	PT1660100E (de)
RS (1)	RS20060154A (de)
RU (1)	RU2348413C2 (de)
UA (1)	UA83500C2 (de)
WO (1)	WO2005023273A1 (de)
ZA (1)	ZA200601852B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2598072C (en) *	2005-03-03	2016-05-03	Massimo Iacobelli	Formulations with anti-tumour action
EP1872787A1 (de) *	2006-06-27	2008-01-02	Gentium S.p.A.	Verwendung von Defibrotide als Heparanasehemmer
EP2103689A1 (de) *	2008-03-19	2009-09-23	Gentium S.p.A.	Synthetische Phosphodiester-Oligonukleotide und deren therapeutische Verwendungen
CN107007617A (zh)	2010-11-12	2017-08-04	真蒂奥姆责任有限公司	去纤维蛋白多核苷酸用于预防和/或治疗移植物抗宿主病(gvhd)
CN104619857A (zh)	2012-06-22	2015-05-13	真蒂奥姆有限公司	用于测定去纤维蛋白多核苷酸的生物活性的基于优球蛋白的方法
EP3026122A1 (de)	2014-11-27	2016-06-01	Gentium S.p.A.	Zellenbasiertes Verfahren zur Bestimmung der Wirksamkeit von Defibrotid
US10380734B2 (en) *	2017-02-27	2019-08-13	Aniket Bharat Parikh	System, method and computer program product for security analysis of jewelry items
AU2018309068A1 (en) *	2017-08-03	2020-02-20	Jazz Pharmaceuticals Ireland Limited	Formulations comprising a nucleic acid in a high concentration
EP3773608A1 (de)	2018-04-12	2021-02-17	Jazz Pharmaceuticals, Inc.	Defibrotid zur vorbeugung und behandlung des zytokinfreisetzungssyndroms und der neurotoxizität im zusammenhang mit immundepletion
WO2020118165A1 (en)	2018-12-07	2020-06-11	Jazz Pharmaceuticals Ireland Limited	Subcutaneous delivery of high concentration formulations
WO2021174039A1 (en)	2020-02-28	2021-09-02	Jazz Pharmaceuticals Ireland Limited	Delivery of low viscosity formulations
TW202308659A (zh)	2021-05-06	2023-03-01	愛爾蘭商爵士製藥愛爾蘭有限責任公司	用於急性呼吸窘迫症候群之治療及預防的去纖維蛋白多核苷酸

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE2154279A1 (de) *	1970-11-03	1972-05-25	Crinos Industria Farmaco	Medikamente für das fibrinolytische System
IT1043823B (it) *	1970-11-03	1980-02-29	Prephar	Procedimento per l estrazione di acidi nucleici da organi animali
US3899481A (en) *	1970-11-03	1975-08-12	Crinos Industria Farmaco	Process for the controlled partial degradation of deoxyribonucleic acid extracted from animal organs
US4853221A (en) *	1980-11-13	1989-08-01	Warner-Lambert Company	Method for treating non-small cell lung cancer, head and neck cancers and breast cancer
IT1170214B (it) *	1983-09-12	1987-06-03	Crinos Industria Farmaco	Composizione farmaceutica per la cura delle arteriopatie periferiche
IT1206341B (it) *	1984-02-16	1989-04-14	Crinos Industria Farmaco	Composizione farmaceutica per il trattamento dell'ischemia acuta del miocardio.
US4694134A (en) *	1985-05-28	1987-09-15	Ajax Magnethermic Corporation	Apparatus for overheating edges of skelp for the production of compression welded pipe
IT1190313B (it) *	1986-04-17	1988-02-16	Crinos Industria Farmaco	Procedimento per l'ottenimento di polidesossiribonucleotidi chimicamente definiti e riproducibili e prodotto farmacologicamente attivo risultante
US5223609A (en) *	1986-04-17	1993-06-29	Crinos Industria Farmacobiologica S.P.A.	Process for obtaining chemically defined and reproducible polydeoxyribonucleotides
US6699985B2 (en) *	1991-08-21	2004-03-02	Arsinur Burcoglu	Method of treating HIV infection and related secondary infections thereof
US5977083A (en) *	1991-08-21	1999-11-02	Burcoglu; Arsinur	Method for using polynucleotides, oligonucleotides and derivatives thereof to treat various disease states
IT1252174B (it) *	1991-12-09	1995-06-05	Crinos Industria Farmaco	Oligodesossimibonucleotidi ad attivita' antiischemica e procedimenti per il loro ottenimento
DE9202745U1 (de)	1992-03-02	1992-04-30	Howmedica Gmbh, 2314 Schoenkirchen	Vorrichtung zum Verspannen von Wirbeln der menschlichen Wirbelsäule
US5578716A (en) *	1993-12-01	1996-11-26	Mcgill University	DNA methyltransferase antisense oligonucleotides
AU754242B2 (en) *	1997-04-28	2002-11-07	Arsinur Burcoglu	Method of treating HIV infection and related secondary infections thereof
AU8125098A (en)	1997-05-30	1998-12-30	Mcgill University	Dna methyltransferase genomic sequences and antisense oligonucleotides
US6177545B1 (en)	1997-09-02	2001-01-23	Insight Strategy & Marketing Ltd.	Heparanase specific molecular probes and their use in research and medical applications
DE19740384A1 (de)	1997-09-08	1999-03-11	Max Delbrueck Centrum	Antisense Oligodesoxynukleotide (ODN) gegen Proteinkinase C (PKC)-Isoformen, ihre Verwendung und pharmazeutische Zubereitungen dieser ODN
KR100903243B1 (ko) *	1999-06-03	2009-06-17	제시 엘. 에스. 에이유	세포증식 및 세포사를 조절하기 위한 방법 및 조성물
PL366223A1 (en) *	2000-12-29	2005-01-24	Bio-Technology General Corp.	Isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6770753B2 (en)	2001-07-05	2004-08-03	The Trustees Of Columbia University In The City Of New York	Phosphorothioate antisense heparanase oligonucleotides
AU2002353783A1 (en)	2001-09-24	2003-04-07	The Government Of The United States Of America As Represented By The Secretary Of The Department Of	SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
US20050032882A1 (en) *	2002-03-06	2005-02-10	Sophie Chen	Botanical extract compositions and methods of use
AU2003238189A1 (en) *	2002-05-31	2003-12-19	Klinikum Der Universitat Regensburg	Method for the protection of endothelial and epithelial cells during chemotherapy
RU2005101621A (ru) *	2002-07-01	2005-11-20	Савиент Фармасьютикалс, Инк. (Us)	Антитела и их применения
CN100345593C (zh)	2002-08-06	2007-10-31	东丽株式会社	用于制备肾脏疾病的治疗或预防药物中的用途
DE10244453A1 (de)	2002-09-24	2004-04-01	Phenomiques Gmbh	Hemmung der Proteinkinase C-alpha zur Behandlung von Krankheiten
US7803781B2 (en)	2003-02-28	2010-09-28	Isis Pharmaceuticals, Inc.	Modulation of growth hormone receptor expression and insulin-like growth factor expression
CA2598072C (en)	2005-03-03	2016-05-03	Massimo Iacobelli	Formulations with anti-tumour action
EP1872787A1 (de)	2006-06-27	2008-01-02	Gentium S.p.A.	Verwendung von Defibrotide als Heparanasehemmer
EP1982722A1 (de)	2007-04-16	2008-10-22	Gentium S.p.A.	Verwendung von Oligotid zur Behandlung von Nierenerkrankungen

2003
- 2003-09-05 IT IT001714A patent/ITMI20031714A1/it unknown
2004
- 2004-08-27 ES ES04764686T patent/ES2308223T3/es active Active
- 2004-08-27 ZA ZA200601852A patent/ZA200601852B/en unknown
- 2004-08-27 CA CA2537226A patent/CA2537226C/en not_active Expired - Fee Related
- 2004-08-27 EP EP04764686A patent/EP1660100B1/de active Active
- 2004-08-27 WO PCT/EP2004/009723 patent/WO2005023273A1/en active IP Right Grant
- 2004-08-27 RS YUP-2006/0154A patent/RS20060154A/sr unknown
- 2004-08-27 JP JP2006525096A patent/JP4671962B2/ja not_active Expired - Fee Related
- 2004-08-27 CN CNB2004800253315A patent/CN100490820C/zh not_active Expired - Fee Related
- 2004-08-27 AU AU2004269896A patent/AU2004269896B2/en not_active Ceased
- 2004-08-27 UA UAA200602374A patent/UA83500C2/uk unknown
- 2004-08-27 MX MXPA06002489A patent/MXPA06002489A/es active IP Right Grant
- 2004-08-27 BR BRPI0414114-8A patent/BRPI0414114A/pt not_active IP Right Cessation
- 2004-08-27 KR KR1020067004451A patent/KR20060061367A/ko not_active Application Discontinuation
- 2004-08-27 PT PT04764686T patent/PT1660100E/pt unknown
- 2004-08-27 AT AT04764686T patent/ATE399558T1/de active
- 2004-08-27 RU RU2006109210/15A patent/RU2348413C2/ru not_active IP Right Cessation
- 2004-08-27 DK DK04764686T patent/DK1660100T3/da active
- 2004-08-27 DE DE602004014787T patent/DE602004014787D1/de active Active
2006
- 2006-02-16 IL IL173785A patent/IL173785A0/en unknown
- 2006-02-28 IS IS8334A patent/IS8334A/is unknown
- 2006-03-02 US US11/366,243 patent/US8551967B2/en not_active Expired - Fee Related
- 2006-03-28 NO NO20061402A patent/NO20061402L/no not_active Application Discontinuation
2013
- 2013-09-06 US US14/019,674 patent/US20140005256A1/en not_active Abandoned

Also Published As

Publication number	Publication date
KR20060061367A (ko)	2006-06-07
WO2005023273A1 (en)	2005-03-17
IL173785A0 (en)	2006-07-05
ATE399558T1 (de)	2008-07-15
US20140005256A1 (en)	2014-01-02
BRPI0414114A (pt)	2006-10-31
PT1660100E (pt)	2008-10-14
ITMI20031714A1 (it)	2005-03-06
EP1660100A1 (de)	2006-05-31
CA2537226C (en)	2016-05-03
IS8334A (is)	2006-02-28
AU2004269896A1 (en)	2005-03-17
MXPA06002489A (es)	2006-06-20
RU2006109210A (ru)	2007-10-10
RU2348413C2 (ru)	2009-03-10
RS20060154A (en)	2008-08-07
ES2308223T3 (es)	2008-12-01
EP1660100B1 (de)	2008-07-02
UA83500C2 (uk)	2008-07-25
AU2004269896B2 (en)	2009-11-19
CN1845746A (zh)	2006-10-11
NO20061402L (no)	2006-03-28
US20060211646A1 (en)	2006-09-21
CA2537226A1 (en)	2005-03-17
DK1660100T3 (da)	2008-11-10
DE602004014787D1 (de)	2008-08-14
JP4671962B2 (ja)	2011-04-20
US8551967B2 (en)	2013-10-08
JP2007504194A (ja)	2007-03-01
CN100490820C (zh)	2009-05-27

Publication	Publication Date	Title
US20140005256A1 (en)	2014-01-02	Formulations with anti-tumour action
Gorelik et al.	1982	Role of NK cells in the control of metastatic spread and growth of tumor cells in mice
TWI359029B (en)	2012-03-01	Liposomes useful for drug delivery
US6906048B2 (en)	2005-06-14	N-acetylcolchinol-O-phosphate combination therapies with vascular damaging activity
EP0114589A1 (de)	1984-08-01	Hemmung der Gefässneubildung
AU2001242581A1 (en)	2002-01-03	Combination therapies with vascular damaging activity
US11351190B2 (en)	2022-06-07	Composition for treating tissue lesions
CN111343984A (zh)	2020-06-26	包含链黑菌素及雷帕霉素作为有效成分的癌症预防或治疗用药学组合物
CN109498627A (zh)	2019-03-22	一种***的药物组合物及其应用
CA2672716C (fr)	2013-05-28	Nouvelle utilisation therapeutique pour le traitement des leucemies
JPH10511677A (ja)	1998-11-10	イノシトール三燐酸の薬剤調製への使用
AU2016330332A1 (en)	2018-04-12	An anti-metastatic marine bacterial exopolysaccharide derivative and uses thereof
CZ20023231A3 (cs)	2003-01-15	Farmaceutické prostředky obsahující činidla poąkozující cévy
JPH07506584A (ja)	1995-07-20	血小板減少症治療における外因性グリコサミノグリカン類または誘導体の利用
US20220339175A1 (en)	2022-10-27	Application of Stachyose in Preparation of Drug for Treating Castration-Resistant Prostate Cancer
Li et al.	2024	Overcoming neutrophil-induced immunosuppression in postoperative cancer therapy: Combined sialic acid-modified liposomes with scaffold-based vaccines
RU2268729C2 (ru)	2006-01-27	Комбинированные терапии с использованием активности, повреждающей сосуды
ZA200207114B (en)	2004-02-04	Combination therapies with vascular damaging activity.